I literally hate this man, what he did,what he represents and what Pfizer did in league with the FDA and DoD re: CV-19 vacks.
That said, the technology of which he is speaking is not new and I have personal experience with the development and eventual approval for marketing of this technology, speaking as one who has had a career in pharmaceutical development spanning > 40 years.
My consulting firm furnished expertise to Otsuka's ABILIFY product line extension which is based on the MIND-1 technology platform. Patient compliance is not a dirty word or term. Too often patients do not derive the benefits of the medications they are prescribed simply due to their failure to take the medicines consistently and as prescribed .
This is particualrly true of patients requiring ABILFY (aripiprazole) which is indicated for patients suffering from schizophrenia, bi-polar disorder, depression, and Tourette's syndrome. I began working with Otsuka in 2013, and ABILIFY was approved by FDA in 2017
The tech works like this: The tablet containing the drug is formulated with an Ingested Event Monitor (IEM) - literally a "battery" which goes live as the tablet disintegrates and the battery contacts stomach fluids. The IEM sends a signal to a small patch which the patient wears, typically on their arm, which in turn sends a signal to the "cloud" which the patient's physician can access and monitor as a regular and real-time follow up on the success of the therapy.
Similarly, and while not an IEM this kind of patch-to-cloud monitoring also exists as it has for many years for diabetes patients who are prescribed a patch to monitor and record sugar "spikes" themselves and also for their physiciani n real-time to monitor the course and effectiveness of diabetes medications which the patient is taking. My own brother in law has such a monitor, because his sugar spikes have been at times severe and his physician has an ability to provide close monitoring of his therapy remotely - without requiring him to come in for expensive and time consuming appointments.
I literally hate this man, what he did,what he represents and what Pfizer did in league with the FDA and DoD re: CV-19 vacks.
That said, the technology of which he is speaking is not new and I have personal experience with the development and eventual approval for marketing of this technology, speaking as one who has had a career in pharmaceutical development spanning > 40 years.
My consulting firm furnished expertise to Otsuka's ABILIFY product line extension which is based on the MIND-1 technology platform. Patient compliance is not a dirty word or term. Too often patients do not derive the benefits of the medications they are prescribed simply due to their failure to take the medicines consistently and as prescribed .
This is particualrly true of patients requiring ABILFY (aripiprazole) which is indicated for patients suffering from schizophrenia, bi-polar disorder, depression, and Tourette's syndrome. I began working with Otsuka in 2013, and ABILIFY was approved by FDA in 2017
The tech works like this: The tablet containing the drug is formulated with an Ingested Event Monitor (IEM) - literally a "battery" which goes live as the tablet disintegrates and the battery contacts stomach fluids. The IEM sends a signal to a small patch which the patient wears, typically on their arm, which in turn sends a signal to the "cloud" which the patient's physician can access and monitor as a regular and real-time follow up on the success of the therapy.
Similarly, and while not an IEM this kind of patch-to-cloud monitoring also exists as it has for many years for diabetes patients who are prescribed a patch to monitor and record sugar "spikes" themselves and also for their physiciani n real-time to monitor the course and effectiveness of diabetes medications which the patient is taking. My own brother in law has such a monitor, because his sugar spikes have been at times severe and his physician has an ability to provide close monitoring of his therapy remotely - without requiring him to come in for expensive and time consuming appointments.
Thanks for your detailed insight.